Ensovibep retains activity with regard to all relevant individual positions mutated in Omicron, the newly discovered viral variant of concern Testing on the full Omicron variant has initiated, with results expected in the coming weeks Global Phase 2-3 EMPATHY clinical study ongoing with topline

Following the futility analysis, the independent Data and Safety Monitoring Board (DSMB) recommends that the recruitment of patients in the ensovibep arm of ACTIV-3 not continue in hospitalized patients The global phase 2-3 EMPATHY study in non-hospitalized patients is still ongoing with topline

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:   Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics,

Ensovibep is shown in vitro to maintain inhibition against all variants of concern known to date The Company is also presenting a Trial in Progress poster on the EMPATHY clinical trial at the conference ZURICH -SCHLIEREN, Switzerland , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX:

- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3

Global rights to registrational-stage ophthalmology drug return to Molecular Partners Improvements in manufacturing and formulation have been made and tested in  pre-clinical models with the potential to overcome inflammatory side effects Ongoing research discovery alliance with AbbVie in

Ensovibep maintains potency in an in vitro assay and demonstrated full inhibition of all newly emerging known variants of concern, including the Delta variants of concern EMPATHY Phase 2/3 trial enrolling ambulatory patients in 5 countries with more countries to be added in the coming months, with